Bridgewater Associates LP Sells 9,138 Shares of Amedisys, Inc. (NASDAQ:AMED)

Bridgewater Associates LP lessened its position in Amedisys, Inc. (NASDAQ:AMED) by 71.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,686 shares of the health services provider’s stock after selling 9,138 shares during the quarter. Bridgewater Associates LP’s holdings in Amedisys were worth $335,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. Blue Trust Inc. raised its holdings in shares of Amedisys by 55.1% in the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares during the last quarter. HBW Advisory Services LLC bought a new position in Amedisys in the fourth quarter valued at $38,000. Versant Capital Management Inc increased its stake in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock valued at $41,000 after buying an additional 183 shares during the last quarter. Vestcor Inc bought a new stake in Amedisys during the 4th quarter worth about $73,000. Finally, Venturi Wealth Management LLC grew its holdings in shares of Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after acquiring an additional 779 shares in the last quarter. Institutional investors own 94.36% of the company’s stock.

Amedisys Stock Performance

AMED opened at $91.76 on Friday. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 12-month low of $82.15 and a 12-month high of $98.95. The business has a 50 day moving average of $92.14 and a 200-day moving average of $91.89. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 36.41, a PEG ratio of 1.78 and a beta of 0.89.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing the consensus estimate of $1.05 by ($0.09). The company had revenue of $598.05 million during the quarter, compared to the consensus estimate of $602.38 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. On average, equities research analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday. Stephens reissued an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.